A New Generation of Metal Anticancer Drugs
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Physical Pharmacy and Formulation".
Deadline for manuscript submissions: 31 May 2025 | Viewed by 54
Special Issue Editor
Interests: nanoparticles; drug delivery; metallodrugs; medicinal chemistry; cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
This Special Issue will explore the latest advancements in the design and development of new metal-based anticancer drugs and studies on their mechanism of actions and the structure–activity relationship, focusing on optimizing therapeutic potential while minimizing toxicity. Metal-containing compounds, such as platinum-based drugs (e.g., cisplatin) and emerging metal complexes, have shown promise in cancer treatment, but their chemoresistance and side effects often pose challenges. In the design of novel metallodrugs, it is vital that problems related to bioavailability, stability, resistance, and side effects are addressed. This Special Issue will delve into novel drug delivery systems, including nanoparticles, liposomes, solid lipid nanoparticles, and conjugated formulations, which enhance the solubility, targeting specificity, and controlled release of metal-based agents. Additionally, it will address the pharmacokinetics and pharmacodynamics of metal-based drugs, highlighting strategies for improving their tissue distribution and tumor accumulation. Researchers and pharmaceutical scientists are invited to contribute insights into the formulation design, formulation characterization, and clinical translation of metal-based anticancer therapies, with the aim of providing safer and more effective treatment options for cancer patients.
Dr. Ignacio E. León
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- metal-based drugs
- cytotoxicity
- cancer
- nanoparticles
- drug delivery
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
